CRTX — CRISM' Therapeutics Share News
0.000.00%
Last trade - 00:00- £7.13m
- £4.86m
- £0.23m
Brief: CRISM Therapeutics Corporation Says Andrew Webb To Continue As Interim Executive Chair
Crism Therapeutics: Board Changes
Brief: Crism Therapeutics Provides Update On Phase 2 Clinical Trial Of Irinotecan-Chemoseed In Glioblastoma
Crism Therapeutics: Phase 2 Clinical Trial Progress Update
Crism Therapeutics: Result of Retail Offer
Crism Therapeutics: Holding(s) in Company
Brief: CRISM' Therapeutics Corp Says Phase 2 Clinical Trial For Irinotecan-ChemoSeed To Begin In Q1 2026
Crism Therapeutics: Half Year Report
Crism Therapeutics: Notice of Interim Results and IMC Presentation
Crism Therapeutics: Approval for phase 2 clinical trial
Crism Therapeutics: AGM Statement
Crism Therapeutics: Notice of AGM and EMI Option Plan
Crism Therapeutics: Holding(s) in Company
Crism Therapeutics: Result of Retail Offer and Additional Placing
RCS - CRISM Therapeutics - Update presentation on the IMC platform
Crism Therapeutics: Retail Offer
Crism Therapeutics: Placing
Crism Therapeutics: Final Results for the year ended 31 December 2024
RCS - CRISM Therapeutics - Best Paper Award